Published in J Biol Chem on December 11, 2003
Progress in matrix metalloproteinase research. Mol Aspects Med (2008) 2.51
MT1-MMP proinvasive activity is regulated by a novel Rab8-dependent exocytic pathway. EMBO J (2007) 2.16
Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis. Semin Cell Dev Biol (2007) 1.50
MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells. Br J Cancer (2007) 1.14
Modulation of the membrane type 1 matrix metalloproteinase cytoplasmic tail enhances tumor cell invasion and proliferation in three-dimensional collagen matrices. J Biol Chem (2009) 1.08
Differentiation of secreted and membrane-type matrix metalloproteinase activities based on substitutions and interruptions of triple-helical sequences. Biochemistry (2007) 1.05
Classically activated macrophages use stable microtubules for matrix metalloproteinase-9 (MMP-9) secretion. J Biol Chem (2012) 1.04
The second dimer interface of MT1-MMP, the transmembrane domain, is essential for ProMMP-2 activation on the cell surface. J Biol Chem (2008) 0.99
The dimer interface of the membrane type 1 matrix metalloproteinase hemopexin domain: crystal structure and biological functions. J Biol Chem (2010) 0.99
Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: high level expression in clear cell carcinoma. Gynecol Oncol (2008) 0.92
The inactive 44-kDa processed form of membrane type 1 matrix metalloproteinase (MT1-MMP) enhances proteolytic activity via regulation of endocytosis of active MT1-MMP. J Biol Chem (2008) 0.90
Epidermal growth factor receptor-mediated membrane type 1 matrix metalloproteinase endocytosis regulates the transition between invasive versus expansive growth of ovarian carcinoma cells in three-dimensional collagen. Mol Cancer Res (2009) 0.89
Identification of a novel 82 kDa proMMP-9 species associated with the surface of leukaemic cells: (auto-)catalytic activation and resistance to inhibition by TIMP-1. Biochem J (2007) 0.88
The cytoplasmic tail dileucine motif LL572 determines the glycosylation pattern of membrane-type 1 matrix metalloproteinase. J Biol Chem (2008) 0.88
Cleavage at the stem region releases an active ectodomain of the membrane type 1 matrix metalloproteinase. Biochem J (2005) 0.87
Retinal pigment epithelium protection from oxidant-mediated loss of MMP-2 activation requires both MMP-14 and TIMP-2. Invest Ophthalmol Vis Sci (2006) 0.85
Glycosylation of Twisted Gastrulation is Required for BMP Binding and Activity during Craniofacial Development. Front Physiol (2011) 0.85
Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: Enhanced surface expression and differential O-glycosylation of MT1-MMP. Biochim Biophys Acta (2010) 0.84
EMMPRIN-mediated induction of uterine and vascular matrix metalloproteinases during pregnancy and in response to estrogen and progesterone. Biochem Pharmacol (2013) 0.81
Activation-coupled membrane-type 1 matrix metalloproteinase membrane trafficking. Biochem J (2007) 0.81
The influence of type 2 diabetes mellitus on the expression of inflammatory mediators and tissue inhibitor of metalloproteinases-2 in human chronic periodontitis. J Periodontal Implant Sci (2011) 0.80
Characterization of the dimerization interface of membrane type 4 (MT4)-matrix metalloproteinase. J Biol Chem (2011) 0.80
Detection of the heterogeneous O-glycosylation profile of MT1-MMP expressed in cancer cells by a simple MALDI-MS method. PLoS One (2012) 0.80
Glycosylation of matrix metalloproteases and tissue inhibitors: present state, challenges and opportunities. Biochem J (2016) 0.77
Bilayer Membrane Modulation of Membrane Type 1 Matrix Metalloproteinase (MT1-MMP) Structure and Proteolytic Activity. Sci Rep (2016) 0.75
Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases. Int J Mol Sci (2016) 0.75
Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature (2011) 6.31
Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol (2007) 6.15
A unified model for apical caspase activation. Mol Cell (2003) 6.12
Mechanisms of caspase activation. Curr Opin Cell Biol (2003) 5.54
The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J (2004) 4.85
The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol (2007) 4.64
Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep (2006) 4.15
Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature (2010) 4.10
Human caspases: activation, specificity, and regulation. J Biol Chem (2009) 3.67
An IAP-IAP complex inhibits apoptosis. J Biol Chem (2004) 2.82
A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci (2005) 2.54
The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J Biol Chem (2005) 2.47
Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins. J Biol Chem (2003) 2.30
XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAPs. EMBO J (2005) 2.27
Activity-based probes that target diverse cysteine protease families. Nat Chem Biol (2005) 2.21
The apoptosome activates caspase-9 by dimerization. Mol Cell (2006) 2.20
The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature (2008) 2.11
Activation of caspases-8 and -10 by FLIP(L). Biochem J (2004) 2.11
TGF-β: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst (2014) 2.08
Metabolic syndrome after hormone-modifying therapy: risks associated with antineoplastic therapy. Oncology (Williston Park) (2010) 2.07
RIPK-dependent necrosis and its regulation by caspases: a mystery in five acts. Mol Cell (2011) 2.06
Emerging principles in protease-based drug discovery. Nat Rev Drug Discov (2010) 2.05
Inducible dimerization and inducible cleavage reveal a requirement for both processes in caspase-8 activation. J Biol Chem (2010) 1.99
Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev (2012) 1.96
Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J (2006) 1.93
Caspases: keys in the ignition of cell death. Chem Rev (2002) 1.91
Membrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc Natl Acad Sci U S A (2004) 1.91
Regulation of the Apaf-1-caspase-9 apoptosome. J Cell Sci (2010) 1.91
Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res (2007) 1.90
Cysteine cathepsins trigger caspase-dependent cell death through cleavage of bid and antiapoptotic Bcl-2 homologues. J Biol Chem (2008) 1.85
Potent mechanism-based inhibitors for matrix metalloproteinases. J Biol Chem (2005) 1.83
Profiling constitutive proteolytic events in vivo. Biochem J (2007) 1.78
Processing, shedding, and endocytosis of membrane type 1-matrix metalloproteinase (MT1-MMP). J Cell Physiol (2004) 1.75
Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res (2004) 1.69
Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis (2008) 1.65
Role of proteolysis in caspase-8 activation and stabilization. Biochemistry (2007) 1.64
Caspases: opening the boxes and interpreting the arrows. Cell Death Differ (2002) 1.64
Small ubiquitin-related modifier (SUMO)-specific proteases: profiling the specificities and activities of human SENPs. J Biol Chem (2007) 1.61
Novel MMP-9 substrates in cancer cells revealed by a label-free quantitative proteomics approach. Mol Cell Proteomics (2008) 1.60
Reprieval from execution: the molecular basis of caspase inhibition. Trends Biochem Sci (2002) 1.53
Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol (2004) 1.52
Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem (2003) 1.52
Structural and kinetic determinants of protease substrates. Nat Struct Mol Biol (2009) 1.52
Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. Cancer Res (2008) 1.51
Design and characterization of a metalloproteinase inhibitor-tethered resin for the detection of active MMPs in biological samples. Chem Biol (2006) 1.50
Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis. Semin Cell Dev Biol (2007) 1.50
Streptolysin O promotes group A Streptococcus immune evasion by accelerated macrophage apoptosis. J Biol Chem (2008) 1.49
Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes. Biochem Biophys Res Commun (2003) 1.48
Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res (2010) 1.46
Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst (2002) 1.45
Transnitrosylation of XIAP regulates caspase-dependent neuronal cell death. Mol Cell (2010) 1.44
Identification of early intermediates of caspase activation using selective inhibitors and activity-based probes. Mol Cell (2006) 1.43
Bone-induced c-kit expression in prostate cancer: a driver of intraosseous tumor growth. Int J Cancer (2014) 1.39
Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res (2005) 1.39
Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography. Methods Mol Biol (2012) 1.38
Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res (2010) 1.38
Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells. J Biol Chem (2004) 1.37
Human caspase-7 activity and regulation by its N-terminal peptide. J Biol Chem (2003) 1.37
DeSUMOylating enzymes--SENPs. IUBMB Life (2008) 1.37
Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res (2005) 1.36
Dominant-interfering forms of MEF2 generated by caspase cleavage contribute to NMDA-induced neuronal apoptosis. Proc Natl Acad Sci U S A (2002) 1.35
Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion. J Biol Chem (2011) 1.35
MT4-(MMP17) and MT6-MMP (MMP25), A unique set of membrane-anchored matrix metalloproteinases: properties and expression in cancer. Cancer Metastasis Rev (2008) 1.34
Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc Natl Acad Sci U S A (2003) 1.34
Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression. Biochem J (2012) 1.33
A constitutively active and uninhibitable caspase-3 zymogen efficiently induces apoptosis. Biochem J (2009) 1.33
Aminopeptidase fingerprints, an integrated approach for identification of good substrates and optimal inhibitors. J Biol Chem (2009) 1.33
Identification of proteolytic cleavage sites by quantitative proteomics. J Proteome Res (2007) 1.32
Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol (2005) 1.32
Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res (2005) 1.32
Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. Int J Cancer (2006) 1.32
Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem J (2005) 1.31
Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res (2011) 1.31
Complementary roles of Fas-associated death domain (FADD) and receptor interacting protein kinase-3 (RIPK3) in T-cell homeostasis and antiviral immunity. Proc Natl Acad Sci U S A (2011) 1.30
Sequential autolytic processing activates the zymogen of Arg-gingipain. J Biol Chem (2003) 1.27
Neutralization of Smac/Diablo by inhibitors of apoptosis (IAPs). A caspase-independent mechanism for apoptotic inhibition. J Biol Chem (2004) 1.27
Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling. J Biol Chem (2013) 1.27
Extracellular matrix-mediated membrane-type 1 matrix metalloproteinase expression in pancreatic ductal cells is regulated by transforming growth factor-beta1. Cancer Res (2006) 1.27
Extracellular proteases as targets for treatment of cancer metastases. Chem Soc Rev (2004) 1.26
Apoptotic caspase activation and activity. Methods Mol Biol (2008) 1.26
Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers. Cancer Res (2007) 1.25
Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collagen-induced EGR1 expression. J Biol Chem (2006) 1.24
Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr Pharm Des (2002) 1.23
Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res (2002) 1.22
Selective hydrolysis of triple-helical substrates by matrix metalloproteinase-2 and -9. J Biol Chem (2003) 1.22
Protection from isopeptidase-mediated deconjugation regulates paralog-selective sumoylation of RanGAP1. Mol Cell (2009) 1.22
Mitochondrial pathway of apoptosis is ancestral in metazoans. Proc Natl Acad Sci U S A (2012) 1.21
Caspase 3 attenuates XIAP (X-linked inhibitor of apoptosis protein)-mediated inhibition of caspase 9. Biochem J (2007) 1.20
Transforming growth factor-beta 1 promotes matrix metalloproteinase-9-mediated oral cancer invasion through snail expression. Mol Cancer Res (2008) 1.19
Molecular structures and dynamics of the stepwise activation mechanism of a matrix metalloproteinase zymogen: challenging the cysteine switch dogma. J Am Chem Soc (2007) 1.19
Activity profiling of human deSUMOylating enzymes (SENPs) with synthetic substrates suggests an unexpected specificity of two newly characterized members of the family. Biochem J (2008) 1.18
Slug is a downstream mediator of transforming growth factor-beta1-induced matrix metalloproteinase-9 expression and invasion of oral cancer cells. J Cell Biochem (2009) 1.18
Regulation of membrane type-matrix metalloproteinases. Semin Cancer Biol (2002) 1.15
Ionomycin-activated calpain triggers apoptosis. A probable role for Bcl-2 family members. J Biol Chem (2002) 1.15
Engineered hybrid dimers: tracking the activation pathway of caspase-7. Mol Cell (2006) 1.14
Intranasal delivery of caspase-9 inhibitor reduces caspase-6-dependent axon/neuron loss and improves neurological function after stroke. J Neurosci (2011) 1.13